NASDAQ · UNCY
Healthcare · Biotechnology
$3.49
Down-$0.25 (-6.68%)
Updated Nov 3, 2026, 9:09 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · UNCY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
UNCY closed at $3.49 after 21 trading sessions, down 16.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $3.60 | $3.61 | $3.33 | $3.49 | 2.24M |
| Oct 30, 2026 | $3.77 | $3.93 | $3.6225 | $3.74 | 1.3M |
| Oct 29, 2026 | $3.77 | $3.87 | $3.74 | $3.81 | 891.63K |
| Oct 28, 2026 | $3.60 | $3.78 | $3.575 | $3.76 | 1.13M |
| Oct 27, 2026 | $3.60 | $3.69 | $3.48 | $3.61 | 1.34M |
| Oct 26, 2026 | $3.90 | $3.90 | $3.53 | $3.58 | 1.33M |
| Oct 23, 2026 | $3.95 | $4.0173 | $3.705 | $3.89 | 1.21M |
| Oct 22, 2026 | $3.87 | $4.00 | $3.83 | $3.94 | 742.89K |
| Oct 21, 2026 | $4.08 | $4.1797 | $3.825 | $3.87 | 1.44M |
| Oct 20, 2026 | $3.53 | $3.87 | $3.52 | $3.80 | 1.21M |
| Oct 19, 2026 | $3.37 | $3.64 | $3.355 | $3.51 | 1.13M |
| Oct 16, 2026 | $3.58 | $3.595 | $3.35 | $3.36 | 1.1M |
| Oct 15, 2026 | $3.70 | $3.7076 | $3.56 | $3.59 | 896.24K |
| Oct 14, 2026 | $3.73 | $3.81 | $3.59 | $3.70 | 1.21M |
| Oct 13, 2026 | $3.99 | $4.02 | $3.67 | $3.73 | 1.84M |
| Oct 12, 2026 | $4.10 | $4.1097 | $3.99 | $4.05 | 912.91K |
| Oct 9, 2026 | $4.07 | $4.20 | $4.05 | $4.11 | 551.39K |
| Oct 8, 2026 | $4.16 | $4.1994 | $4.0301 | $4.07 | 1.18M |
| Oct 7, 2026 | $4.15 | $4.22 | $4.08 | $4.18 | 590.78K |
| Oct 6, 2026 | $4.20 | $4.2938 | $4.15 | $4.23 | 786.42K |
| Oct 5, 2026 | $4.22 | $4.275 | $4.12 | $4.19 | 681.4K |
The latest Smart Investors Daily articles mentioning UNCY.
Company
Market Activity
Research & News
UNCY research
Company profile and research snapshot.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2026 | Benchmark | Speculative Buy | — |
| Aug 13, 2026 | Guggenheim | Buy | — |
| Aug 13, 2026 | B. Riley Securities | Buy | — |
| Jul 1, 2026 | Benchmark | Speculative Buy | — |
No generated briefing is available yet.
Yahoo · Oct 21, 2026
Resubmission includes Chemistry, Manufacturing, and Controls (CMC) data from new drug product (DP) manufacturing vendorMountain View, California – Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.
Yahoo · Oct 21, 2026
Resubmission includes Chemistry, Manufacturing, and Controls (CMC) data from new drug product (DP) manufacturing vendor MOUNTAIN VIEW, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbona
Benzinga · Oct 21, 2026
Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S.
Yahoo · Oct 13, 2026
Unicycive Therapeutics (UNCY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning UNCY.
